Key result
Percutaneous PDA closure during infancy achieved a technical success rate of 92.2% with an overall adverse event incidence of 23.3%.
Why the study?
Is percutaneous PDA closure technically successful and safe in infants (<1 year of age)?
Meta-Analysis
Is percutaneous PDA closure technically successful and safe in infants (<1 year of age)?
Percutaneous PDA closure during infancy is feasible with a high technical success rate, though it carries a 10.1% risk of clinically significant adverse events and is limited by the lack of comparative studies.
Answers are grounded in this paper and cite their sources.
Supports feasibility of percutaneous PDA closure in infants; leaves open need for comparative trials versus surgery.
CONTEXT: Patent ductus arteriosus (PDA) is a precursor to morbidity and mortality. Percutaneous (catheter-based) closure is the procedure of choice for adults and older children with a PDA, but use during infancy (<1 year) is not well characterized. OBJECTIVE: Investigate the technical success and safety of percutaneous PDA closure during infancy. DATA SOURCES: Scopus, Web of Science, Embase, PubMed, and Ovid (Medline) were searched through December 2015 with no language restrictions. STUDY SELECTION: Publications needed to clearly define the intervention as percutaneous PDA closure during infancy (<1 year of age at intervention) and must have reported adverse events (AEs). DATA EXTRACTION: The study was performed according to the Systematic Reviews and Meta-Analysis checklist and registered prospectively. The quality of the selected studies was critically examined. Data extraction and assignment of AE attributability and severity were independently performed by multiple observers. Outcomes were agreed on a priori. Data were pooled by using a random-effects model. RESULTS: Thirty-eight studies were included; no randomized controlled trials were found. Technical success of percutaneous PDA closure was 92.2% (95% confidence interval [CI] 88.8-95.0). Overall AE and clinically significant AE incidence was 23.3% (95% CI 16.5-30.8) and 10.1% (95% CI 7.8-12.5), respectively. Significant heterogeneity and publication bias were observed. LIMITATIONS: Limitations include lack of comparative studies, lack of standardized AE reporting strategy, and significant heterogeneity in reporting. CONCLUSIONS: Percutaneous PDA closure during infancy is feasible and associated with few catastrophic AEs; however, the limitations constrain the interpretability and generalizability of the current findings.
No takes yet. Share an insight, caveat, or question.
Backes et al. (2017) conducted a meta-analysis in Patent ductus arteriosus (PDA). Percutaneous PDA closure was evaluated on Technical success (95% CI 88.8-95.0). Percutaneous PDA closure during infancy achieved a technical success rate of 92.2% with an overall adverse event incidence of 23.3%.
Synapse has enriched 10 related papers. Consider them for comparative context: